PRELUDE THERAPEUTICS INC Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation
PRELUDE THERAPEUTICS INC (PRLD) reported Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation of 3.86 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC share-based payment arrangement, shares withheld for tax withholding obligation for the quarter ending 2026-06-30 was 3.86K shares, a 15.08% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, shares withheld for tax withholding obligation for the quarter ending 2026-03-31 was 21.43K shares, a 455.22% increase year-over-year.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, shares withheld for tax withholding obligation for the quarter ending 2025-09-30 was 3.35K shares, a 9.86% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, shares withheld for tax withholding obligation for the quarter ending 2025-06-30 was 3.35K shares, a 9.86% decline year-over-year.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, shares withheld for tax withholding obligation for fiscal 2025 was 13.92K shares, a 9.91% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, shares withheld for tax withholding obligation for fiscal 2024 was 15.46K shares, a 288.02% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC share-based payment arrangement, shares withheld for tax withholding obligation for fiscal 2023 was 3.98K shares.
| Period end | Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.86K shares 10-Q · filed 2026-08-11 | 25.29K shares derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | 21.43K shares 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | 13.92K shares 10-K · filed 2026-03-10 | |||
| 2025-09-30 | 3.35K shares 10-Q · filed 2025-11-12 | 6.71K shares derived: sum of 2 quarters · filed 2026-08-11 | 10.57K shares derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | 3.35K shares 10-Q · filed 2026-08-11 | 7.21K shares derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | 3.86K shares 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | 15.46K shares 10-K · filed 2026-03-10 | |||
| 2024-09-30 | 3.72K shares 10-Q · filed 2025-11-12 | 7.44K shares derived: sum of 2 quarters · filed 2025-11-12 | 11.73K shares derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | 3.72K shares 10-Q · filed 2025-11-12 | 8.01K shares derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | 4.29K shares 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | 3.98K shares 10-K · filed 2025-03-10 | |||
| 2023-09-30 | 3.61K shares 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |